Endocrine System Diseases
Global pharmaceutical companies face significant challenges in developing therapies for autoimmune and inflammatory diseases affecting the endocrine system. By leveraging our expertise, we strive to provide innovative services in diagnostics, therapy development, animal model creation, and preclinical research.
Introduction to Endocrine System Autoimmune Diseases
Endocrine system autoimmune and inflammatory diseases occur when the immune system mistakenly attacks the body's endocrine glands or tissues, leading to dysregulation of hormonal function and subsequent inflammation. These conditions can affect various endocrine organs, including the thyroid, pancreas, adrenal glands, and more. Common examples of such diseases include Hashimoto's thyroiditis, type 1 diabetes, Addison's disease, and autoimmune polyglandular syndrome.
Effects of the Immune System on the Stress System
The intricate interplay between the immune system and the stress system, particularly the Hypothalamic-Pituitary-Adrenal (HPA) axis, holds significant importance in the context of endocrine system autoimmune and inflammatory diseases. Stress can exert an impact on immune function, while immune responses can in turn influence stress levels. During acute inflammation, the immune system releases proinflammatory cytokines and other molecules that activate the HPA axis. Consequently, corticotropin-releasing hormone (CRH), adrenocorticotrophic hormone (ACTH), and glucocorticoids are released, aiding in the suppression of the inflammatory reaction and restoration of homeostasis. This bidirectional relationship underscores the intricate connection between the immune and stress systems in the context of endocrine-related autoimmune and inflammatory diseases.
Fig.1 Endocrine tissue and immune diseases. (Kohanim Y. K., et al., 2020)
Value of Therapy Development for Endocrine System Autoimmune Diseases
Higher incidence rates of autoimmune diseases affecting the endocrine system are observed among women. For instance, autoimmune thyroid diseases, including hyperthyroidism and autoimmune thyroiditis, are more prevalent in women. Additionally, individuals with a family history of these diseases are at an increased risk. Age and environmental factors also play a role in the prevalence of autoimmune endocrine disorders. In the face of these challenges, the development of effective drugs and therapies becomes crucial. Consequently, pharmaceutical companies are actively investing in research focused on autoimmune diseases of the endocrine system. The following highlights some of the drugs and companies currently involved in these endeavors.
| Condition (Endocrine System Autoimmune Diseases) | Drug Name | Organization | Phase |
|---|---|---|---|
| Hashimoto's Thyroiditis | ABI-001 | Alpha Cancer Technologies | Phase I |
| Diabetes Type 1 | cePolyTregs | University of California, San Francisco | Phase I |
| Addison Disease | prasterone | Paladin | Phase II |
| Graves' Disease | Rituximab | Natl Inst Diabetes Digest Kidney Dis | Phase II/III |
| Thyroid-associated Ophthalmopathy (Graves Ophthalmopathy) | batoclimab | Immunovant | Phase III |
Our Services
At our company, we pride ourselves on our extensive range of services dedicated to endocrine system autoimmune and inflammatory diseases. Our diagnostic and therapy development services encompass state-of-the-art techniques, including biomarker analysis, and diagnostic kit development.
Types of Endocrine System Autoimmune Diseases
The development of therapies for autoimmune and inflammatory diseases of the endocrine system poses huge challenges to global pharmaceutical companies. At our company, our commitment to cutting-edge research and development drives us to provide innovative therapy development services.
Furthermore, our expertise in animal model development enables us to simulate and study the pathogenesis of endocrine system autoimmune and inflammatory diseases in preclinical research. We conduct comprehensive studies to investigate the mechanisms of action of novel drug candidates, assess their pharmacokinetics and pharmacodynamics, and evaluate their potential side effects. Through rigorous testing and analysis, we strive to identify promising therapeutic options that can advance to clinical trials.
If you are interested in our services, please don't hesitate to contact us.
References
- Kohanim Y. K., et al. "Endocrine autoimmune disease as a fragility of immune surveillance against hypersecreting mutants." Immunity 52.5 (2020): 872-884.
- Uccella S., et al. "Inflammatory and infectious disorders in endocrine pathology." Endocrine Pathology 34.4 (2023): 406-436.